Verastem Oncology Announces Andrei Shustov, M.D., Recipient of 2nd Annual Innovation in Care Award

November 13, 2019 at 7:00 AM EST

BOSTON--(BUSINESS WIRE)--Nov. 13, 2019-- Verastem, Inc. (Nasdaq: VSTM), (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that Andrei Shustov, M.D., Professor of Medicine and Hematology, University of Washington, Associate Member, Clinical Research Division, Fred Hutchinson Cancer Research Center and President and Founder of the T-Cell Leukemia and Lymphoma Foundation (TCLLF) has been selected to receive the Company's Innovation in Care Award.

The Verastem Oncology Innovation in Care Award recognizes individuals, organizations or teams who are leading the way in advancing the principles of patient-focused care, including coordination and integration of care, engaging patients, families, and caregivers in providing comprehensive support as well as collaborating with others in the cancer care system for ongoing quality improvement.

"Recognizing a critical lack of resources available to those affected by T-cell leukemias and lymphomas, Dr. Shustov has dedicated his career to breaking new ground to expand support and research efforts to those affected by these diseases," said Brian Stuglik, Chief Executive Officer of Verastem Oncology. "As a company, we aim to follow the example of leaders like Dr. Shustov as we not only seek to deliver therapies that keep cancer at bay, but also continually look to innovate to improve the lives of those diagnosed with cancer."

The TCLLF is committed to providing reliable, accurate and quality resources to patients, family members, caregivers and medical professionals looking to learn more about T-cell leukemias and lymphomas. Its patient education forums give direct access to T-cell leukemia/lymphoma specialists, which allows them the opportunity to learn more about their specific disease and ask personalized questions. The Foundation has also recently started sponsoring an annual *T-Cell Leukemia/Lymphoma Young Investigator Grant* with the goal of producing valuable research efforts and encouraging new oncologists/hematologists to specialize in the treatment of these diseases.

"Patients and their families affected by rare lymphoid malignancies like T-cell lymphomas have very limited resources available to them to learn about their disease and its management. With knowledge comes hope and power to take charge in making important decisions regarding one's life, and all patients deserve that," said Dr. Shustov. "The fight with cancer, like lymphomas, only begins in the doctor's offices and treatment centers; the real challenge faces patients and families at home. This aspect of patient care always felt missing. Filling this gap and providing patients with education, access to expert opinions, and opportunity to connect with other patients and families, were the inspirations behind the founding of TCLLF."

The Verastem Oncology Innovation in Care Award will be presented to Dr. Shustov at a Verastem Oncology reception on December 6, 2019 during the American Society of Hematology (ASH) meeting in Orlando, FL. Last year, the inaugural award recipient was Brian Koffman, M.D., founder and volunteer Medical Director of the nonprofit CLL Society (CLLS). Since his own CLL diagnosis in 2005, Dr. Koffman has dedicated himself to teaching and advocating on behalf of the CLL community.

About Verastem Oncology

Verastem Oncology (Nasdaq: VSTM) is a commercial biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer. We are driven by the strength, tenacity and courage of those battling cancer – single-minded in our resolve to deliver new therapies that not only keep cancer at bay but improve the lives of patients diagnosed with cancer. Because for us, it's personal.

Our first FDA approved product is now available for the treatment of patients with certain types of indolent non-Hodgkin's lymphoma (iNHL). Our pipeline comprises product candidates that seek to treat cancer by modulating the local tumor microenvironment. For more information, please visit www.verastem.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191113005067/en/

Source: Verastem, Inc.

Investors:
John Doyle
Vice President, Investor Relations & Finance
+1 781-469-1546
jdoyle@verastem.com

Media:
Lisa Buffington
Corporate Communications
+1 781-292-4205
lbuffington@verastem.com